Abstract: One or more electronic device may use motion and/or activity sensors to estimate a user's 6 minute walking distance. In particular, because users typically walk at less than their maximum output and in imperfect conditions, control circuitry within the device(s) may rely on walks of shorter distances to estimate the 6 minute walking distance. For example, the control circuitry may gather activity information for the user, such as heart rate, calories burned, and step count, and analyze a distance component and a speed component for periods in which the user has walked. Individual 6 minute walk distance estimates may be generated based on each of the activity information, distance component, and speed component. The distance and speed estimates may be corrected for walking behaviors that deviate from an ideal testing environment, and may then be fused with the activity estimate to generate a final 6 minute walk distance estimate.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Embodiments are disclosed for stride length estimation and calibration at the wrist. In some embodiments, a method comprises: obtaining sensor data from a wearable device worn on a wrist of a user; deriving features from the sensor data; estimating a form-based stride length using an estimation model that takes the features and user height as input; and calibrating the form-based stride length. In other embodiments, user cadence and speed are used to estimate speed-based stride length which, upon certain conditions, is blended with the form-based stride length to get a final estimated stride length of the user.

Abstract: Enclosed are embodiments for estimating gait time events and GCT using a wrist-worn device. In some embodiments, a method comprises: obtaining, with at least one processor of a wrist-worn device, sensor data indicative of acceleration and rotation rate; and predicting, with the at least one processor, at least one gait event time based on a machine learning (ML) model with the acceleration and rotation rate as input to the ML model.

Abstract: Enclosed are embodiments for estimating vertical oscillation (VO) at the wrist. In some embodiments, a method comprises: obtaining, with a wearable device worn on a wrist of a user, sensor data indicative of the user's acceleration and rotation rate; estimating centripetal acceleration based on the user's acceleration and rotation rate; calculating a modified user's acceleration by subtracting the estimated centripetal acceleration from the user's acceleration; estimating center of mass (CoM) acceleration by decoupling an arm swing component of the user's acceleration from the modified user's acceleration; and computing vertical oscillation of the user's CoM using a machine learning model with at least the CoM acceleration as input to the machine learning model, or by integrating vertical acceleration derived from the CoM acceleration and a gravity vector.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Compounds having the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract: Embodiments are disclosed for identifying poor cardio metabolic health using sensors of wearable devices. In an embodiment, a method comprises: obtaining estimates of maximal oxygen consumption of a user during exercise; determining at least one confidence weight based on context data; adjusting the maximal oxygen consumption estimates using the at least one confidence weight; aggregating the adjusted maximal oxygen consumption estimates to generate a summary maximal oxygen consumption estimate and corresponding confidence interval for the user; and classifying cardiorespiratory fitness of the user based on at least one of the summary maximum consumption estimate, the corresponding confidence interval, a population error model or a low cardiorespiratory fitness threshold.

Abstract: Embodiments are disclosed for assessing fall risk of a mobile device user. In some embodiments, a method comprises: obtaining one or more mobility metrics indicative of a user’s mobility, the mobility metrics obtained at least in part from sensor data output by at least one sensor of the mobile device; evaluating the one or more mobility metrics over one or more specified time periods to derive one or more longitudinal features; estimating a plurality of walking steadiness indicators based on a plurality of component models and the one or more longitudinal features; inferring the user’s risk of falling based at least in part on the plurality of walking steadiness indicators; and initiating an action or application on the mobile device based at least in part on the user’s risk of falling.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The invention presents a covered cavity kiln pyrolyzer with modulated means of rotation, to promote mixing and exposure of the biomass to heat, thereby allowing complete and efficient pyrolysis of biomass therein. The invention has a portal arrangement for simultaneous entry of fuel and air alongside the exit of emissions and flames to a separate hood structure. In addition to rotational modulation for mixing, the rotational capabilities of the kiln also permit the removal of processed charcoal when the portal is turned downward. The invention also has a system of internal prongs for mixing and sifting removal of char, as well as automated fuel delivery mechanisms and a system of openings to allow insertion of pipes and sensors into the kiln for monitoring and for additional delivery of reagents for better modulation and efficiency by a user during the pyrolyzation process.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: Y is Formula (II), or Formula (III); R1, R2, R2a, R2b, R2c, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The invention presents a covered cavity kiln pyrolyzer with modulated means of rotation, to promote mixing and exposure of the biomass to heat, thereby allowing complete and efficient pyrolysis of biomass therein. The invention has a portal arrangement for simultaneous entry of fuel and air alongside the exit of emissions and flames to a separate hood structure. In addition to rotational modulation for mixing, the rotational capabilities of the kiln also permit the removal of processed charcoal when the portal is turned downward. The invention also has a system of internal prongs for mixing and sifting removal of char, as well as automated fuel delivery mechanisms and a system of openings to allow insertion of pipes and sensors into the kiln for monitoring and for additional delivery of reagents for better modulation and efficiency by a user during the pyrolyzation process.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CR1 or N; and G, A, R1; and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.